title: Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series.
abstract: Hyperglycaemia may develop after whole-pancreas transplantation (PTX) in patients with type 1 diabetes mellitus (T1DM), but the efficacy and tolerability of GLP-1 receptor agonists have not been assessed in this population. This report is a 6-month prospective follow-up of six T1DM recipients of PTX (mean time after PTX: 68.8 ± 45.7 months), all of whom had an HbA1c>6.5% (48 mmol/mol) [mean: 7.1% (54 mmol/mol)] after initiation of liraglutide alone at 0.6 mg once daily titrated to 1.2mg once daily at week 1. Gastrointestinal disorders were reported in three of the six patients, with discontinuation of liraglutide in only one patient. HbA1c improved in the five remaining patients, with a median decrease of 0.8% (0.0-2.7%) at 6 months, and the median decrease in body weight was 2.0 kg. Immunosuppressive treatments remained unchanged with liraglutide. Thus, liraglutide appears to be an effective and well-tolerated option in PTX patients with impaired glucose homoeostasis, regardless of the cause.
authors.affiliation: Department of Endocrinology, l'Institut du Thorax, University Hospital of Nantes, 44000 Nantes, France; Université de Nantes, Faculté de Médecine, Institut du Thorax, 44000 Nantes, France; INSERM, UMR1087-CNRS UMR6291, l'Institut du Thorax, 44000 Nantes, France. Electronic address: bertrand.cariou@univ-nantes.fr.
authors.forename: B
authors.initials: B
authors.lastname: Cariou
authors.affiliation: Department of Endocrinology, l'Institut du Thorax, University Hospital of Nantes, 44000 Nantes, France.
authors.forename: C
authors.initials: C
authors.lastname: Bernard
authors.affiliation: Institut de Transplantation-Urologie-Néphrologie (ITUN), Inserm UMR 1064, Nantes University Hospital, 44000 Nantes, France.
authors.forename: D
authors.initials: D
authors.lastname: Cantarovich
mesh_terms: D000328:Adult; D001835:Body Weight; D003967:Diarrhea; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000069450:Liraglutide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009325:Nausea; D016035:Pancreas Transplantation; D010865:Pilot Projects; D011446:Prospective Studies
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide
keywords: GLP-1 receptor agonist; Pancreas transplantation; Type 1 diabetes